Articles by Tag - Lou Gehrig
Tuesday, February 7, 2023
How many people in the United States have amyotrophic lateral sclerosis (ALS) at any one time is a difficult – and often fraught – question.
read more
Tuesday, February 7, 2023
We are proud of the progress that we have made thus far in 2022 and we look forward to continuing to share detailed updates at the 2022 ALS TDI Summit on October 14th.
read more
Tuesday, February 7, 2023
Many in the ALS research community believe that, in light of what we now know about the disease, these terms are not entirely accurate.
read more
Tuesday, February 7, 2023
AT-1501, a drug invented at the ALS Therapy Development Institute (ALS TDI) and being developed by Eledon Pharmaceuticals, has a new name: tegoprubart.
read more
Tuesday, February 7, 2023
The study is expected to be completed in March, 2022, with topline results coming later in the year.
read more
Tuesday, February 7, 2023
After over a decade of service, ALS TDI’s beloved Development Director, Terri Handler, will be retiring at the end of 2021. Here we talk about her experience and her lasting contribution to ALS TDI’s mission to end ALS.
read more
Tuesday, February 7, 2023
At the ALS Therapy Development Institute (ALS TDI), we love it when video gamers show up to support
read more
Tuesday, February 7, 2023
"I know that ALS TDI will continue to work until there are treatments for everyone living with ALS, but they need our help." - Tavares Speer
read more
Tuesday, February 7, 2023
This year's Summit program included updates about drug discovery research programs in various stages of development at ALS TDI, as well as an extensive update on Project Euphonia from Google.
read more
Tuesday, February 7, 2023
Much of what causes the 90% of Amyotrophic Lateral Sclerosis (ALS) cases that are sporadic remains a
read more

Showing 1 to 10 of 23 results

 

Loading...